HLA Data Systems, LLC
Healthcare LIMS SaaS · Acquired by CareDx · Houston, TX
GSV INVESTED
$750,000
Two tranches · Mar–Jul 2021
TOTAL PROCEEDS
$2,060,047
Incl. earnout payments
REALIZED MOIC
2.75x
Gross multiple
HOLD PERIOD
~22 mo
Mar 2021 → Jan 2023
ACQUIRER
CareDx
NASDAQ: CDNA
EXECUTIVE SUMMARY
A Textbook Niche SaaS Exit
Source: GS Value Tracker Dec 2025, Officer Certificate Jan 2023, HLA Longform Deal Memo
HLA Data Systems represents one of Golden Section's most capital-efficient and cleanest exits from Fund I. GSV invested $750K in March 2021 at a $3.3M pre-money valuation into a niche healthcare LIMS provider serving HLA (Human Leukocyte Antigen) transplant laboratories. Within 22 months, the company was acquired by CareDx (NASDAQ: CDNA), a leading transplant diagnostics company, generating $2.06M in total proceeds — a 2.75x MOIC.
The deal validates GS's thesis of investing in "boring" but mission-critical vertical SaaS with deep domain moats, sticky customer bases, and clear strategic acquirer profiles. HLA's exit to CareDx was a natural platform tuck-in: CareDx needed transplant lab workflow software to complement its diagnostics suite, and HLA's mTilda product had been the gold-standard LIMS in HLA labs for over a decade.
In a period where SaaS multiples were contracting sharply (2022–2023), HLA's exit at a meaningful premium demonstrates that niche vertical SaaS with genuine product-market fit and strategic value can still command strong outcomes even in down markets.
ARR TRAJECTORY (USD ANNUALIZED FROM VALUE TRACKER)
ENTRY ARR
~$925K
Oct 2020 (at diligence)
EXIT ARR
~$1.5M
Estimated at acquisition
INVESTMENT SCORECARD
Return Analysis & Value Creation
Source: GS Value Tracker Dec 2025, Capitalization Model, Signed Term Sheet
2.75x
REALIZED MOIC
$2.06M on $750K invested
~73%
GROSS IRR
22 month hold period
18.5%
GSV OWNERSHIP
FD post-investment
$3.3M
PRE-MONEY VAL
~3.6x entry ARR
INVESTMENT ECONOMICS
Total Capital Deployed$750,000
Tranche 1 (Closing)$375,000
Tranche 2 (+120 days)$375,000
Total Proceeds$2,060,047
Gross Profit$1,310,047
Entry Multiple (Pre/ARR)3.6x ARR
Implied Exit Valuation~$11.1M
Implied Exit Multiple~7.4x ARR
VALUE TRACKER SNAPSHOT
DEAL STRUCTURE & TIMELINE
From Diligence to Exit in 26 Months
Source: Signed Term Sheet Mar 2021, Officer Certificate Jan 2023, Deal Memo Nov 2020
INVESTMENT TERMS
| Security Type | Partner Preferred Stock (Series A Units) |
| Total Investment | $750,000 |
| Pre-Money Valuation | $3,300,000 |
| Post-Money Valuation | $4,050,000 |
| Liquidation Preference | 1x participating + 8% cumulative dividend |
| Board Seats | 2 of 5 (+ 1 mutual consent) |
| Redemption | 5-year hard redemption at FMV |
| Investor Entity | GSV Investors I LP |
| Acquirer | CareDx Transplant Management, Inc. |
| Exit Structure | Membership Interest Purchase Agreement |
KEY TIMELINE
Nov 2020
Deal Memo Presented to GPs
Initial thesis: $750K at $2.7M pre-money, targeting 8x MOIC in 5 years
Mar 2021
Term Sheet Signed & Tranche 1
$375K deployed at $3.3M pre-money (revised up from $2.7M)
Jul 2021
Tranche 2 Deployed
Remaining $375K invested; $250K allocated to pay down company debt
2022
Revenue Growth & Strategic Interest
ARR grew above $1.2M; CareDx began acquisition discussions
Jan 2023
Acquisition by CareDx Closes
Full exit via Membership Interest Purchase Agreement; GSV receives $2.06M
WHAT GS DID RIGHT
Five Pillars of a Successful Niche SaaS Investment
Source: Deal Memo, Term Sheet, Value Tracker, Tech Diligence
Identified a "boring" but mission-critical niche. HLA labs are a small ($40M SAM) but essential part of the transplant ecosystem. GS recognized that the small market size was actually a moat — too small for large competitors to enter, but large enough for a dominant player to build a highly profitable business. This counter-consensus thesis proved exactly right.
GP-level domain knowledge and relationship. Adam Day (GP) was already a personal investor in HLA and knew the management team intimately. This insider knowledge dramatically de-risked the investment — GS understood the team's capabilities, the product's strengths, and the market dynamics at a level most investors could never achieve in traditional diligence.
Disciplined entry valuation. At $3.3M pre-money (~3.6x ARR of $925K), GS entered at a very reasonable price for a profitable, growing vertical SaaS business. This left meaningful upside even in a moderate exit scenario and ensured downside protection via the participating preferred structure.
Structured strong investor protections. The 1x participating preference with 8% cumulative dividend, 2 of 5 board seats, and hard redemption rights created a robust safety net. These protections were critical — they ensured GSV would get a meaningful return even in a below-thesis exit scenario.
Recognized the strategic acquirer landscape early. The deal memo explicitly identified that the product could be acquired by larger healthcare IT platforms. CareDx (a NASDAQ-listed transplant diagnostics company) was precisely the type of strategic buyer GS envisioned — one that needed workflow software to complement its existing diagnostics suite.
Capital-efficient growth without dilution. HLA had consumed only $500K to reach $925K ARR before GS invested. The $750K investment was used surgically: pay down $250K of debt, invest in product, and build a professional sales process — not to fund a cash-burning growth-at-all-costs strategy.
FUND I COMPARATIVE ANALYSIS
HLA vs. Fund I Portfolio — Efficiency Matters
Source: GS Value Tracker Dec 2025
| COMPANY | SECTOR | INVESTED | CURRENT VALUE / PROCEEDS | MOIC | STATUS |
|---|---|---|---|---|---|
| HLA Data Systems | Healthcare Tech / B2B SaaS | $750K | $2,060,047 | 2.75x | EXITED |
| Brokerage Engine | Property Tech / Marketplace | $2,069K | $5,393K (current) | 2.26x | ACTIVE |
| Kare | Healthcare Tech / Marketplace | $2,915K | $75,785K (current) | 7.52x | ACTIVE |
| Freight Train | Logistics Tech / B2B SaaS | $1,000K | $1,131K (current) | 0.99x | ACTIVE |
| Accelerist | Nonprofit Tech / B2B SaaS | $1,140K | $0 (write-off) | 0.0x | EXITED |
CAPITAL DEPLOYED VS. MOIC (FUND I)
HLA CAPITAL EFFICIENCY
$1.74 returned per $1 invested
Net profit $1.31M on $750K invested in just 22 months
HLA AS % OF FUND I EXITS
100% of realized DPI
Only profitable exit in Fund I to date (Accelerist was a write-off)
KEY INSIGHT
Smallest check, fastest exit, cleanest return
HLA proves that small, disciplined bets in niche verticals can deliver outsized risk-adjusted returns
MARKET CONTEXT & EXIT TIMING
Exiting at the Right Time in a Down Market
Source: Market data, Deal Memo, Value Tracker
HLA's exit closed in January 2023 — right in the middle of the worst SaaS valuation compression since the dot-com bust. Public SaaS multiples had crashed from 15-20x ARR in late 2021 to 5-7x ARR by early 2023. Many private SaaS companies found themselves unable to raise follow-on rounds, let alone exit.
Yet HLA Data Systems commanded a strategic premium because of several factors that are highly instructive for future portfolio management:
Strategic vs. financial buyer = premium. CareDx didn't buy HLA for its revenue multiple — they bought it for the product's integration into their transplant platform. Strategic acquirers are less sensitive to public market multiples.
Healthcare is recession-resistant. Unlike adtech, e-commerce, or SMB SaaS, HLA's hospital and lab customers don't churn during downturns. Transplant labs must operate regardless of economic conditions. This revenue durability made the business attractive even in a risk-off environment.
Profitability is the ultimate moat. HLA was cash-flow positive and growing — a rare combination in 2022-2023. The company didn't need to raise more capital at depressed valuations, giving the team leverage to negotiate from strength rather than desperation.
SAAS MARKET ENVIRONMENT AT EXIT (Q1 2023)
PUBLIC SAAS MULTIPLES
5-7x ARR
Down from 15-20x in late 2021
HLA IMPLIED EXIT MULTIPLE
~7.4x ARR
Above market median — strategic premium
PRIVATE SAAS FUNDRAISING
Down ~40% YoY
Many companies forced into down rounds or exits
KEY TAKEAWAY
Niche vertical SaaS with strategic value commands premium multiples even in compressed markets. Financial buyers disappeared — strategic buyers stepped in.
LESSONS LEARNED
Eight Takeaways for Future Investments & Exits
Source: Post-mortem analysis across all source documents
LESSON 01
Small TAM Is a Feature, Not a Bug
HLA's $40M SAM scared away other investors. But for a $750K check targeting a $25M exit, a $40M market with one weak competitor is ideal. Small markets create natural monopolies. GS should continue to look for "$40M market, one competitor" situations.
LESSON 02
GP Personal Investment = Conviction Signal
Adam Day's personal investment in HLA before the fund deal provided invaluable inside knowledge and alignment. When a GP has skin in the game pre-fund, the diligence quality is fundamentally different. This pattern should be tracked as a leading indicator of deal quality.
LESSON 03
Prioritize Profitability-First SaaS
HLA operated above Rule of 40 with just $500K of lifetime capital consumed. In hindsight, this was the single most important quality during the 2022-2023 downturn. Profitable companies can choose when to exit; unprofitable ones get forced. Future underwriting should weight capital efficiency more heavily.
LESSON 04
Map the Strategic Acquirer Landscape at Entry
The deal memo identified strategic exit paths, and CareDx was exactly the type of buyer envisioned. For every investment, GS should maintain a live list of 5-10 strategic acquirers and actively build relationships with their BD teams starting from Year 1.
LESSON 05
Legacy Tech Risk Was Manageable
GST's tech diligence flagged the legacy codebase as a risk. In reality, the decade-old product was stable and well-suited for its purpose. For vertical SaaS, "boring tech that works" often beats "modern tech still in beta." The acquirer valued the product's reliability, not its architecture.
LESSON 06
Participating Preferred Protects Downside
The 1x participating preference with 8% cumulative dividend ensured GSV would earn a meaningful return even in a modest exit. For small-check deals, strong structural protections are non-negotiable — they turn "okay" exits into good ones.
LESSON 07
Healthcare Vertical SaaS Exits Well in Any Market
Both HLA (exited) and Kare (Fund I's top performer at 7.52x MOIC) are healthcare tech. The sector's combination of regulatory moats, mission-critical use cases, and recession-resistant demand creates a favorable exit environment regardless of macro conditions. GS should overweight healthcare vertical SaaS.
LESSON 08
Know When to Take the Exit
HLA's 2.75x in 22 months is not a 10x return. But it's a clean, realized return with zero drama. In a portfolio context, realized DPI matters more than paper MOIC. The original thesis projected 8.34x MOIC over 5 years — getting 2.75x in less than 2 years was a better risk-adjusted outcome. Don't let perfect be the enemy of good.
RISK RETROSPECTIVE
What We Worried About vs. What Happened
Source: Deal Memo Risk Assessment, Post-Exit Analysis
RISKS IDENTIFIED AT ENTRY
HIGH
Legacy Tech Re-architecture
GST flagged that the core product would need significant re-engineering. Outcome: CareDx acquired the product as-is and integrated it into their platform. The acquirer took on the tech debt — not a problem for GS.
GST flagged that the core product would need significant re-engineering. Outcome: CareDx acquired the product as-is and integrated it into their platform. The acquirer took on the tech debt — not a problem for GS.
MED
Small Market Size ($40M SAM)
Concern that the addressable market was too small to support a meaningful exit. Outcome: The small market was precisely what made HLA dominant and attractive to a strategic acquirer. The "risk" was actually the thesis.
Concern that the addressable market was too small to support a meaningful exit. Outcome: The small market was precisely what made HLA dominant and attractive to a strategic acquirer. The "risk" was actually the thesis.
MED
CEO-Led Sales Dependency
Michael Reardon (CEO/PhD) was the primary salesperson, relying on SME-led sales. Outcome: The specialized sales model proved effective for this market. The $750K investment was used in part to professionalize the sales process.
Michael Reardon (CEO/PhD) was the primary salesperson, relying on SME-led sales. Outcome: The specialized sales model proved effective for this market. The $750K investment was used in part to professionalize the sales process.
LOW
Customer Concentration
A handful of marquee hospital customers. Outcome: These blue-chip customers (Stanford, MSKCC, Wake Forest) were actually a selling point to CareDx — they validated the product's quality.
A handful of marquee hospital customers. Outcome: These blue-chip customers (Stanford, MSKCC, Wake Forest) were actually a selling point to CareDx — they validated the product's quality.
RISKS WE DIDN'T ANTICIPATE
HIGH
SaaS Market Meltdown (2022-2023)
Nobody predicted the severity of the SaaS valuation reset. HLA's profitability and strategic value shielded it, but other portfolio companies were not so fortunate.
Nobody predicted the severity of the SaaS valuation reset. HLA's profitability and strategic value shielded it, but other portfolio companies were not so fortunate.
MED
Accelerated Exit Timeline
The original thesis was a 5-year hold to $5M ARR. Getting an exit offer at 22 months with ~$1.5M ARR required a decision: hold for more upside or take the certain return? The team wisely chose certainty.
The original thesis was a 5-year hold to $5M ARR. Getting an exit offer at 22 months with ~$1.5M ARR required a decision: hold for more upside or take the certain return? The team wisely chose certainty.
LOW
Earnout Structure Complexity
Part of the proceeds came through an earnout arrangement. While ultimately successful, earnouts add execution risk and timeline uncertainty.
Part of the proceeds came through an earnout arrangement. While ultimately successful, earnouts add execution risk and timeline uncertainty.
KEY INSIGHT FOR GP
The biggest risks identified at entry (tech debt, small market) turned out to be non-issues or even advantages. The biggest actual risk (macro environment) was unforeseeable. This reinforces the importance of structural protections and business-level resilience over risk-factor analysis.
EXIT PLAYBOOK FOR CURRENT PORTFOLIO
Applying HLA's Lessons to Future Exits
Source: HLA Exit Analysis, Current SaaS Market Conditions 2025-2026
With SaaS valuations still under pressure in 2025-2026 and rising interest rates keeping financial buyers cautious, HLA's exit playbook offers a proven template for maximizing portfolio value:
PLAYBOOK 01
Build Strategic Acquirer Relationships Early
Start BD conversations with potential acquirers 12-18 months before target exit. HLA's exit to CareDx was a natural fit — identify similar fits for every portfolio company now. Create a "Strategic Acquirer Map" for each investment.
PLAYBOOK 02
Push Portfolio Companies to Profitability
In the current environment, Rule of 40 compliance is table stakes. Companies burning cash have zero exit leverage. Prioritize path-to-profitability plans for every company below breakeven. Cash-flow positive companies can wait for the right buyer.
PLAYBOOK 03
Don't Wait for "Perfect" — Take Good Exits
HLA's 2.75x in 22 months was better risk-adjusted than holding for a speculative 8x over 5 years. In a compressed market, realized returns beat paper returns. Review every portfolio company for "good enough" exit opportunities quarterly.
PLAYBOOK 04
Leverage Participating Preferred in Negotiations
HLA's participating preferred structure ensured meaningful downside protection. For portfolio companies approaching exit, model the waterfall to understand where GS returns fall under different scenarios and negotiate accordingly.
PLAYBOOK 05
Healthcare & Mission-Critical Verticals First
Healthcare SaaS (HLA, Kare) has outperformed every other sector in Fund I. In future funds, overweighting healthcare and other regulation-heavy verticals (fintech compliance, government, defense) provides built-in exit resilience.
PLAYBOOK 06
Earnout Structures Can Bridge Valuation Gaps
HLA's earnout component bridged the gap between what the buyer would pay upfront and what GS felt the company was worth. In a down market, earnouts are a useful tool — but ensure milestones are achievable and measurable.
GP ALERT — CURRENT PORTFOLIO ACTION ITEMS
Based on HLA's lessons, immediately assess: (1) which portfolio companies are cash-flow positive and could attract strategic buyers today, (2) which companies need a bridge to profitability and what that costs, (3) which companies have identifiable strategic acquirer fits similar to HLA → CareDx. Schedule a portfolio-wide "Exit Readiness Review" within 30 days.
TEAM & GOVERNANCE
The People Behind the Exit
Source: Deal Memo, Officer Certificate, Capitalization Model
MR
Michael Reardon, PhD
CEO
Deep HLA domain expert and primary sales driver. PhD-level credibility gave mTilda unmatched trust in a highly technical buyer community. Led the company through the CareDx acquisition process.
CB
Collin Brack
PRESIDENT & SECRETARY
Co-managed operations and served as President. 20.9% equity owner pre-investment. Executed on day-to-day operations and was a signatory on both the investment and exit documents.
BU
Barbara Ure
CHIEF SOFTWARE ARCHITECT
Architect of the mTilda platform. Maintained and evolved the decade-old LIMS through multiple SaaS iterations. Key to the product's stability and customer trust.
AD
Adam Day
CFO & GS GP
GS GP who was already a personal investor in HLA. Served as CFO, bringing financial discipline and investor-grade reporting. Largest individual equity holder at 36.5% pre-investment (27.1% post-investment). His dual role was a key differentiator.
BOARD COMPOSITION AT EXIT
5 board seats per term sheet: Collin Brack (company), Michael Reardon (company), 1 mutual consent director, Dougal Cameron (GSV), Adam Day (GSV). GSV held 2 of 5 board seats plus the CFO role — providing strong governance oversight while maintaining operational flexibility for the management team.
GP RETROSPECTIVE VERDICT
Verdict: SUCCESSFUL EXIT — TEMPLATE FOR FUND II
HLA Data Systems stands as Golden Section's cleanest and most instructive exit to date. The investment validates every core element of the GS thesis: niche vertical SaaS, mission-critical product, disciplined entry valuation, strong structural protections, and patient capital deployed into a capital-efficient business. The 2.75x MOIC in 22 months, achieved during the worst SaaS market correction in a decade, demonstrates that the playbook works — even when macro conditions turn hostile.
The most important lesson for Fund II and beyond: focus on companies that don't need favorable market conditions to exit well. HLA's profitability, strategic value, and monopoly-like position in its niche made it exit-ready at any point. This is the standard every portfolio company should be measured against.
The GP team should institutionalize HLA's exit playbook — strategic acquirer mapping from Day 1, profitability-first operating plans, and quarterly exit-readiness reviews — across the entire portfolio. The next HLA is already in the portfolio. The question is whether we're running the same playbook for it.
The most important lesson for Fund II and beyond: focus on companies that don't need favorable market conditions to exit well. HLA's profitability, strategic value, and monopoly-like position in its niche made it exit-ready at any point. This is the standard every portfolio company should be measured against.
The GP team should institutionalize HLA's exit playbook — strategic acquirer mapping from Day 1, profitability-first operating plans, and quarterly exit-readiness reviews — across the entire portfolio. The next HLA is already in the portfolio. The question is whether we're running the same playbook for it.
REALIZED MOIC
2.75x
$2.06M on $750K invested
ESTIMATED GROSS IRR
~73%
22-month hold period
EXIT PATH
Strategic M&A to NASDAQ-listed acquirer (CareDx)
TOP LESSON
Small TAM + Monopoly Position = Exit Premium
The market size "risk" was actually the thesis
REPLICATE FOR
Brokerage Engine, Freight Train
Active F1 companies with similar niche profiles
WATCH OUT FOR
Holding too long for "max" MOIC
Realized DPI > paper MOIC in uncertain markets
Prepared by Derek · March 2026 · Sources: GS Value Tracker Dec 2025, HLA Longform Deal Memo, Signed Term Sheet Mar 2021, Officer Certificate Jan 2023, HLA Capitalization Model, P&L Statements 2016-2021, Company Summary Presentation, Tech Diligence Report